New hope for tough cancers: experimental drug IL-22BP enters human testing
NCT ID NCT07040943
First seen Apr 23, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This early-stage trial is testing a new drug called IL-22BP in about 6 adults with advanced solid tumors that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. Participants must be between 18 and 70 years old and in relatively good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiation Oncology
RECRUITINGChengdu, Sichuan, 610000, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact
Conditions
Explore the condition pages connected to this study.